NCT04731818已完成早期 1 期
An Exploratory Phase 1 Mechanism-of-action Study of ZB-06, a Vaginal Film Containing HC4-N, an Anti-sperm Monoclonal Antibody.
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 发起方
- KBio Inc
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Surrogate Contraceptive Efficacy
研究概览
简要总结
This is an early Phase 1 study to establish proof-of-concept by determining whether an intravaginal film containing a human contraceptive antibody (ZB-06) shows promise to provide contraceptive efficacy using the post-coital test, a surrogate measure of efficacy. The study will also evaluate the safety and pharmacokinetics of ZB-06.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18 - 50 years, inclusive
- •General good health, by volunteer history and per investigator judgment
- •History of regular menstrual cycles of 21 - 35 days (inclusive), by volunteer report
- •History of a normal PAP smear or ASCUS with negative HPV testing within the previous 12 months
- •Willing to abstain from intercourse and use of vaginal medications, lubricants, and other products as required in the protocol
- •Willing to use non-spermicidal, lubricated condoms for any vaginal intercourse from the first day of each menstrual cycle until 72 hours before expected midcycle
- •In a mutually monogamous relationship with a male partner who:
- •Is at least 18 years old
- •Has no known risk for sexually transmitted infections (STIs)
- •Is willing and able to comply with protocol requirements including sexual activity/ abstinence and condom use requirements
- •Can engage in vaginal intercourse with the participant, with and without condoms, as specified in protocol
- •Protected from pregnancy by female surgical sterilization
- •Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy genital tract sample collection
- •Willing to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol
排除标准
- •History of hysterectomy
- •Surgical sterility or known history of infertility in male partner
- •Sterility or known history of sperm dysfunction in male partner
- •Currently pregnant by urine pregnancy test at the enrollment visit, or within two calendar months from the last pregnancy outcome. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome
- •Current use of any hormonal contraceptive or a copper or hormonal IUD, or use of Depo-Provera in the last 120 days
- •Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study
- •Significant gynecological abnormalities (including abnormal vaginal bleeding, excessive vaginal discharge, or vulvar/vaginal pain or irritation)
- •Current UTI, vaginal candidiasis, or symptomatic bacterial vaginosis
- •History of sensitivity/allergy to ZB-06 film components, for either the volunteer or her male partner
- •In the last three months, either the volunteer or her male partner diagnosed with or treated for any STI or pelvic inflammatory disease, or either partner with known risk factors for sexually transmitted infections. Note: Women with a history of genital herpes or condylomata who have been asymptomatic for at least six months may be considered for eligibility
- •Positive test for Trichomonas vaginalis, Neisseria gonorrhea, Chlamydia trachomatis, or HIV at the screening visit
- •Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for an STI
- •Known current drug or alcohol abuse which could impact study compliance
- •Participation in any other investigational trial within the last 30 days or planned participation in any other investigational trial during the study
- •History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days
- •Abnormal finding on laboratory or physical examination or a social or medical condition in either the volunteer or her male partner which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data
研究组 & 干预措施
ZB-06
Experimental
All participants will receive a single ZB-06 film for intravaginal administration prior to intercourse.
干预措施: ZB-06 (Biological)
结局指标
主要结局
Surrogate Contraceptive Efficacy
时间窗: 2-3 hours after sexual intercourse.
Number of progressively motile sperm in aspirated endocervical mucus when using ZB-06 prior to intercourse.
次要结局
- Adverse Events(Baseline through study exit encompassing a minimum of three menstrual cycles of 21-35 days.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)Cervical Intraepithelial Neoplasia Grade 2/3High-risk HPV (Any Strain)NCT02354534Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins30
招募中
不适用
Phase I study: to determine the biological activity of two HPV16 E6 specific peptides coupled to Amplivant®, a Toll-like receptor ligand in nonmetastatic patients treated for HPV16-positive head and neck cancerNL-OMON41192eids Universitair Medisch Centrum24
已完成
1 期
Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or EmtricitabineHIVNCT01694407CONRAD48
已完成
1 期
Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in BelgiumHIV InfectionsNCT00332995International Partnership for Microbicides, Inc.13
进行中（未招募）
不适用
Ensayo clínico en Fase I-IIa para conocer la factibilidad y seguridad del uso alogénico de células madre expandidas (e-ASC) derivadas de la grasa en el tratamiento local de fístulas recto-vaginales de Crohn.Tratamiento local de fístulas recto-vaginales.EUCTR2009-010225-39-ESFundación para la Investigación Biomédica del Hospital Universitario La Paz